Keywords: BioMarin Pharma, Zacharon Pharma, M&A, MPS disorders, Glycobiology
BioMarin acquires Zacharon Pharma for upfront $10 million
Article | 08 January 2013
US drugmaker BioMarin Pharmaceutical (Nasdaq: BMRN) says it has acquired Zacharon Pharmaceuticals, a privately-held biotechnology company based in San Diego ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
